-
2019年12月以来, 湖北省武汉市陆续发现了新型冠状病毒肺炎病人, 随着疫情的发展, 我国其他地区及境外也相继发现了此类病例。2月11日, 世界卫生组织总干事谭德赛宣布, 新型冠状病毒感染的肺炎将正式被命名为“2019冠状病毒病(COVID-19)”。国家疾病预防控制中心宣布将COVID-19纳入国家“乙类”传染病, 采取“甲类”传染病防控措施[1]。近期, 有关COVID-19的基础、临床及流行病学研究不断报道[2-6]。在我国举全国之力采取积极有效的防控措施和广大医务人员的努力下, 疫情已基本得到控制, 但在境外, 特别是意大利、西班牙等国, 病例数仍在迅速增长, 且死亡率较高。我们在临床救治工作中发现部分普通型病人可以很短时间内向重型病人演变, 甚至演变为危重型, 给提高救治成功率带来很大困难。如何早期发现该部分病人将对提高诊治水平有很大价值。本文分析我院收治的24例普通型向重型演变COVID-19病人的临床资料, 并与同期41例普通型病人的临床资料作比较, 分析COVID-19病人普通型向重型演变的可能危险因素。
-
演变组在合并基础疾病和呼吸频率上与普通型组比较差异有统计学意义(P<0. 05), 但在性别、年龄和临床症状上2组病人差异均无统计学意义(P>0. 05)(见表 1)。
分组 n 男 女 年龄/岁 合并基础疾病 临床症状 主要体征/(次/分) < 40 40~50 51~60 ≥60 0~1种 ≥2种 发热 咳嗽/咳痰 胸闷气喘 其他 < 24 ≥24 演变组 24 15 9 1 4 12 7 13 11 21 8 3 0 16 8 普通型组 41 20 21 5 11 15 10 36 5 41 12 1 1 36 5 χ2 — 1.15 2.52 13.32 3.41 6.13 P — >0.05 >0.05 <0.05 >0.05 <0.05 表 1 2组病人临床特征比较(n)
-
对2组病人的入院后第2天血液学指标比较,演变组淋巴细胞计数和血浆白蛋白明显低于普通型组(P<0.01)。血糖和尿素演变组明显高于普通型组(P<0.01)。2组在白细胞计数、血小板计数及丙氨酸氨基转移酶差异均无统计学意义(P>0.05)(见表 2)。
分组 n 白细胞计数/
(×109/L)淋巴细胞计数/
(×109/L)血小板计数/
(×109/L)白蛋白/
(g/L)ALT/
(U/L)血糖/
(mmol/L)尿素/
(μmol/L)演变组 24 6.34±3.68 0.98±0.53 237.58±125.53 35.03±5.92 42.88±41.83 8.84±3.88 5.97±2.96 普通型组 41 6.42±3.53 1.56±0.55 257.68±84.12 40.01±3.85 36.73±34.71 6.51±1.86 3.74±1.31 t — 0.09 4.16 0.77 4.11 0.63 3.27 4.19 P — >0.05 <0.01 >0.05 <0.01 >0.05 <0.01 <0.01 表 2 2组病人的血液学指标比较(x±s)
-
演变组IL-6和CRP明显高于普通型组(P<0.01)(见表 3)。
分组 n IL-6/(pg/mL) CRP/(mg/L) 演变组 24 9.88±4.59 47.88±16.63 普通型组 41 6.69±4.23 28.35±14.91 t — 2.84 4.88 P — <0.01 <0.01 表 3 2组病人的炎性指标比较(x±s)
-
根据65例COVID-19病人的CT影像学表现,较为典型的征像有:(1)单发磨玻璃阴影;(2)多发外周胸膜下磨玻璃阴影;(3)双肺磨玻璃阴影、斑片状影及实变影同时存在;(4)双肺弥漫性磨玻璃阴影伴支气管充气征;(5)大面积实变影伴肺间质改变(见图 1~5)。2组病人的影像学表现差异有统计学意义(P<0.05)。虽然2组影像学表现中均为多发外周胸膜下磨玻璃阴影和双肺磨玻璃阴影、斑片状影及实变影同时存在为主,但演变组中以双肺磨玻璃阴影、斑片状影及实变影同时存在影像学表现比例最高,普通型组以多发外周胸膜下磨玻璃阴影比例最高(χ2=10.92, P<0.05)(见表 4)。
分组 n 单发磨
玻璃阴影多发外周胸膜下
磨玻璃阴影双肺磨玻璃阴影、
斑片状影及实变影双肺弥漫性磨玻璃
阴影伴支气管充气征大面积实变影
伴肺间质改变演变组 24 1(4.17) 3(12.50) 12(50.00) 7(29.16) 1(4.17) 普通型组 41 8(19.51) 17(41.46) 10(24.39) 6(14.64) 0(0.00) 合计 65 9(13.85) 20(30.77) 22(33.85) 13(20.00) 1(1.54) 表 4 2组病人的影像学表现比较[n;百分率(%)]
-
对于COVID-19临床抗病毒治疗,演变组2种抗病毒药物联合20例,3种药物联合4例,普通型组分别为35例、6例,2组差异无统计学意义(χ2=0.05,P>0.05),三种药物联合并没有减少向重型演变。
普通型向重型演变的新型冠状病毒肺炎病人的危险因素分析
Analysis of the risk factors of the common type evolving into severe type COVID-19
-
摘要:
目的 探讨新型冠状病毒肺炎(COVID-19)病人普通型向重型演变的临床危险因素。 方法 收集24例普通型向重型演变COVID-19病人的临床资料(演变组),分析临床特征、血液检验、炎性指标、胸部CT影像学特征及抗病毒治疗,并与同期41例普通型病人(普通型组)的临床资料进行比较,分析COVID-19病人普通型向重型演变的可能危险因素。 结果 临床特征,演变组在合并基础疾病和呼吸频率上与普通型组比较差异有统计学意义(P<0.05),但在性别、年龄和临床症状上2组病人差异无统计学意义(P>0.05)。血液学检验结果分析,演变组淋巴细胞计数和血浆白蛋白明显低于普通型组(P<0.05),演变组血糖和尿素明显高于普通型组(P<0.05)。但在白细胞计数、血小板计数及丙氨酸氨基转移酶差异均无统计学意义(P>0.05)。演变组炎性指标明显高于普通型组(P<0.05)。COCID-19普通型病人影像学表现为双肺磨玻璃阴影、斑片状影及实变影,双肺弥漫性磨玻璃阴影伴支气管充气征,两肺大面积实变影伴肺间质改变更易向重型演变,临床应重视。两种抗病毒药物联合和三种药物联合,在演变组和普通型组间差异无统计学意义(P>0.05)。 结论 COVID-19普通型向重型演变的可能危险因素有合并基础疾病、呼吸频率、淋巴细胞计数、血糖、白蛋白、尿素水平、炎症因子和影像学表现。 Abstract:Objective To investigate the clinical risk factors of common type evolving into severe type corona virus disease 2019 (COVID-19). Methods The clinical data of 24 patients with common type evolving into severe type COVID-19 were collected(evolution group), the clinical characteristics, blood test results, inflammatory indexes, chest CT imaging characteristics and antiviral treatment were analyzed, which was compared with the clinical data of 41 patients with common type COVID-19 patients(common type group).The possible risk factors of COVID-19 patients developing from common type to severe type were analyzed. Results For the clinical characteristics between evolution group and common type group, the differences of the complication with underlying disease and respiratory rate were statistically significant(P<0.05), and the differences of the sex, age and clinical symptoms were not statistically significant(P>0.05).The results of blood test showed that the lymphocyte counts and plasma albumin level in evolution group were significantly lower than those in common type group(P<0.05), the blood glucose and urea levels in evolution group were significantly higher than those in common type group(P<0.05), and the differences of the white blood cell count, platelet count and alanine aminotransferase levels between two groups were not statistically significant(P>0.05).The inflammatory indexes in evolution group were significantly higher than that in common type group(P<0.05).The double lung ground glass shadow, patchy shadow and consolidation shadow, double lung with diffuse ground glass shadow complicated with bronchogram were the mainly imaging findings of the common type group, and the common type patients with two lung large area consolidation shadow complicated with pulmonary interstitial change were more likely to develop to severe type.The differences of the clinical effects of two and three kinds of drugs treatment between two groups were not statistically significant(P>0.05). Conclusions The combination of underlying diseases, respiratory frequency, lymphocyte count, blood glucose, albumin, urea level, inflammatory factors and imaging manifestations are the possible risk factors of common type evolving into severe type COVID-19. -
Key words:
- corona virus disease 2019 /
- common type /
- severe type /
- risk factor
-
表 1 2组病人临床特征比较(n)
分组 n 男 女 年龄/岁 合并基础疾病 临床症状 主要体征/(次/分) < 40 40~50 51~60 ≥60 0~1种 ≥2种 发热 咳嗽/咳痰 胸闷气喘 其他 < 24 ≥24 演变组 24 15 9 1 4 12 7 13 11 21 8 3 0 16 8 普通型组 41 20 21 5 11 15 10 36 5 41 12 1 1 36 5 χ2 — 1.15 2.52 13.32 3.41 6.13 P — >0.05 >0.05 <0.05 >0.05 <0.05 表 2 2组病人的血液学指标比较(x±s)
分组 n 白细胞计数/
(×109/L)淋巴细胞计数/
(×109/L)血小板计数/
(×109/L)白蛋白/
(g/L)ALT/
(U/L)血糖/
(mmol/L)尿素/
(μmol/L)演变组 24 6.34±3.68 0.98±0.53 237.58±125.53 35.03±5.92 42.88±41.83 8.84±3.88 5.97±2.96 普通型组 41 6.42±3.53 1.56±0.55 257.68±84.12 40.01±3.85 36.73±34.71 6.51±1.86 3.74±1.31 t — 0.09 4.16 0.77 4.11 0.63 3.27 4.19 P — >0.05 <0.01 >0.05 <0.01 >0.05 <0.01 <0.01 表 3 2组病人的炎性指标比较(x±s)
分组 n IL-6/(pg/mL) CRP/(mg/L) 演变组 24 9.88±4.59 47.88±16.63 普通型组 41 6.69±4.23 28.35±14.91 t — 2.84 4.88 P — <0.01 <0.01 表 4 2组病人的影像学表现比较[n;百分率(%)]
分组 n 单发磨
玻璃阴影多发外周胸膜下
磨玻璃阴影双肺磨玻璃阴影、
斑片状影及实变影双肺弥漫性磨玻璃
阴影伴支气管充气征大面积实变影
伴肺间质改变演变组 24 1(4.17) 3(12.50) 12(50.00) 7(29.16) 1(4.17) 普通型组 41 8(19.51) 17(41.46) 10(24.39) 6(14.64) 0(0.00) 合计 65 9(13.85) 20(30.77) 22(33.85) 13(20.00) 1(1.54) -
[1] 中华人民共和国国家卫生健康委员会.新型冠状病毒感染的肺炎诊疗方案[EB/OL]. [2] HUANG C, WANG Y, LI X, et al.Clinicalfeatures of patients infected with 2019 novel coronavirus in Wuhan, China[J].Lancet, 2020, 395(10223):497. doi: 10.1016/S0140-6736(20)30183-5 [3] WANG D, HU B, HU C, et al.Clinical characteristics of 138 hospitalized patients with 2019 Novel Coronavirus-infected pneumonia in Wuhan, China[J].JAMA, 2020.DOI:10.1001/jama.2020.1585. [4] CHAN JF, YUAN S, KOK KH, et al.A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission:a study of a family cluster[J].Lancet, 2020, 395(10223):514. doi: 10.1016/S0140-6736(20)30154-9 [5] REN LL, WANG YM, WU ZQ, et al.Identification of a novel coronavirus causing severe pneumonia in human:a descriptive study[J].Chinese Med J, 2020.DOI:10.1097/CM9.0000000000000722. [6] CHEN Y, LIU Q, GUO D, et al.Emerging coronaviruses:Genome structure, replication, and pathogenesis[J].J Med Virol, 2020, 92(4):418. doi: 10.1002/jmv.25681 [7] GRALINSKI LE, MENACHERY VD.Return of the Coronavirus:2019-nCoV[J].Viruses, 202012(2).DOI:10.3390/v12020135. [8] 华中科技大学同济医学院附属同济医院救治医疗专家组.新型冠状病毒感染的肺炎诊疗快速指南(第三版)(EB/OL).https://www.tjh.com.cn/html/2020/0128/28713.shtml#title.[2020-1-28]. [9] BENVENUTO D, GIOVANNETTI M, CICCOZZI A, et al.The 2019-new coronavirus epidemic:evidence for virus evolution[J].J Med Virol, 2020.DOI:10.1002/jmv.25688. [10] LI Q, GUAN X, WU P, et al.Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia[J].N Engl J Med, 2020.DOI:10.1056/NEJMoa2001316. [11] GUO L, WEI D, ZHANG X, et al.Clinical features predicting mortality risk in patients with viral pneumonia:the MuLBSTA score[J].Front Microbiol, 2019, 10:2752. doi: 10.3389/fmicb.2019.02752 [12] 陈蕾, 刘辉国, 刘威, 等.2019新型冠状病毒肺炎29例临床特征分析[J].中华结核和呼吸杂志, 2020, 43(3):203. doi: 10.3760/cma.j.issn.1001-0939.2020.03.013 [13] CASTRUCCI MR.Factors affecting immune responses to the influenza vaccine[J].Hum Vaccin Immunother, 2018, 14(3):637. [14] LA GRUTA NL, KEDZIERSKA K, STAMBAS J, et al.A question of self-preservation:immunopathology in influenza virus infection[J].Immunol Cell Biol, 2007, 85(2):85. doi: 10.1038/sj.icb.7100026 [15] YANG PH, ING YB, XU Z et al.Epidemiological and clinical features of COVID-19 patients with and without pneumonia in Beijing, China[J].Medrxiv, 2020.DOI:10.1101/2020.02.28.20028068 -
20200401.pdf